Valuation: Opus Genetics, Inc.

Market Cap 282M 247M 230M 212M 397M 26.9B 404M 2.73B 1.07B 13.34B 1.06B 1.03B 46.09B P/E 2026 *
-3.18x
P/E 2027 * -4.49x
Enterprise Value 282M 247M 230M 212M 397M 26.9B 404M 2.73B 1.07B 13.34B 1.06B 1.03B 46.09B EV / Sales 2026 *
18.5x
EV / Sales 2027 * 19x
Free-Float
88.96%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day-1.32%
1 week+12.46%
Current month-16.55%
1 month-15.52%
3 months-26.55%
6 months+37.20%
Current year+70.65%
1 week 2.82
Extreme 2.82
3.5
1 month 2.82
Extreme 2.82
4.39
Current year 1.88
Extreme 1.88
5.81
1 year 1.04
Extreme 1.04
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 31/10/2023
Director of Finance/CFO 52 01/09/2025
President 60 21/10/2024
Director TitleAgeSince
Director/Board Member 77 31/10/2020
Chairman 56 30/11/2019
Director/Board Member 59 31/10/2020
Date Insider Type Main position Quantity % Market Cap.
23/07/26 Sell

Chief Executive Officer

-9,475 0.0115%
23/07/26 Sell

Chairperson

-7,429 0.0090%
23/07/26 Sell

Chief Operating Officer

-4,644 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
-1.32%+12.46%+200.88%-20.79% 282M
-0.08%+4.89%+59.89%+168.37% 1,089B
+0.16%+4.58%+59.03%+59.58% 643B
+1.01%+4.71%+38.70%+77.31% 465B
-1.02%+9.75%+40.58%+34.81% 359B
-0.60%+3.65%+37.16%+42.66% 303B
+1.46%+3.48%+17.80%+17.50% 267B
+0.47%+5.52%-2.81%-38.26% 226B
+0.18%+8.04%+30.28%+68.90% 212B
-1.08%+2.52%+16.98%+75.51% 167B
Average -0.11%+5.71%+49.85%+48.56% 373.14B
Weighted average by Cap. +0.06%+5.14%+42.99%+82.06%

Financials

2026 *2027 *
Net sales 15.18M 13.32M 12.41M 11.41M 21.39M 1.45B 21.76M 147M 57.61M 719M 56.99M 55.76M 2.49B 14.83M 13.02M 12.12M 11.15M 20.9M 1.42B 21.26M 144M 56.28M 703M 55.68M 54.48M 2.43B
Net income -94.49M -82.93M -77.22M -71.03M -133M -9.03B -135M -916M -359M -4.48B -355M -347M -15.47B -67.77M -59.47M -55.38M -50.94M -95.49M -6.47B -97.13M -657M -257M -3.21B -254M -249M -11.09B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
29/07/26 US$3.425 +0.44% 72,386
28/07/26 US$3.410 +1.79% 669,911
27/07/26 US$3.350 +8.77% 538,747
24/07/26 US$3.080 +5.48% 1,089,572
23/07/26 US$2.920 -4.26% 1,453,407
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
3.410USD
Average target price
10.56USD
Spread / Average Target
+209.55%

Quarterly revenue - Rate of surprise